| Next 10 |
INGN News and Press Inogen Inc
-
Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Tom West to Inogen’s Board of Directors, effective April 1, 2023. The company also announced that Kristen Miranda, w...
-
Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will participate in a virtual fireside chat at the KeyBanc Virtual Life Sciences & MedTech Investor Forum on Tuesday, Marc...
-
2023-03-06 13:46:43 ET Summary Supply chain issues caused major problems for Inogen in FY22, and continued headwinds are expected in FY23. Management expects operational performance to improve in late FY23 but indicates that returning to profitability is a medium-to-long-term ende...
-
Inogen Inc. (INGN) Q4 2022 Results Conference Call February 23, 2023 05:00 PM ET Company Participants Agnes Lee - SVP of IR and Strategic Planning Nabil Shabshab - President and CEO Kristin Caltrider - CFO Conference Call Participants Matthew Blackman - Sti...
-
Inogen press release ( NASDAQ: INGN ): Q4 Non-GAAP EPS of -$0.57 beats by $0.08 . Revenue of $88.09M (+15.3% Y/Y) misses by $1.61M . For further details see: Inogen Non-GAAP EPS of -$0.57 beats by $0.08, revenue of $88.09M misses by $1.61M
-
Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will host a conference call on Monday, February 27, 2023, at 10:00 a.m. Eastern Time. At the event, Nabil Shabshab, President and Chie...
-
Fourth Quarter Year-over-Year Revenue Growth of 15.3% Full Year 2022 Year-over-Year Revenue Growth of 5.4% Inogen, Inc . (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial resu...
-
The shares of Inogen Inc. ( NASDAQ: INGN ) fell in the morning hours Tuesday after William Blair downgraded the MedTech company to Market Perform from Outperform, citing the impact of macro headwinds on medical equipment. “….we believe that there could be more headwinds ...
-
Inogen ( NASDAQ: INGN ) estimates Q4 total revenue to be in the range of $87.5M to $88.5M, representing Y/Y growth of 14.5% to 15.8%, vs consensus of $89.48M . FY22 total revenue is expected to be in the range of $376.7M to $377.7M, representing Y/Y growth of 5.2% to...
-
Inogen Announces Receipt of EU Quality Management Certification under the Medical Device Regulation for Portable Oxygen Concentrators Inogen Announces U.S. Food and Drug Administration 510(k) clearance for its Latest Portable Oxygen Concentrator Inogen to Launch New Rove Series Po...
Stock Information
Get INGN Alerts
News, Short Squeeze, Breakout and More Instantly...